NHS Weight Loss Injections – Who Qualifies and How to Access

Weight loss injections available through the NHS include Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide). Access is tightly controlled, with eligibility tied to specific BMI thresholds and weight-related health conditions. A phased rollout began in 2025, prioritising patients with the most severe obesity-related complications.

These medications are prescribed alongside diet, exercise, and lifestyle support programmes rather than as standalone treatments. Patients must meet strict clinical criteria before they can receive prescriptions, and the NHS has implemented a tiered system to manage demand while ensuring those with greatest clinical need receive access first.

Understanding the eligibility requirements, associated costs, and potential side effects is essential for anyone considering NHS-funded weight loss treatment. Regional variations also mean that availability may differ across England, Scotland, and Wales.

What are the criteria for NHS weight loss injections?

NHS weight loss injections are reserved for patients meeting specific clinical thresholds, primarily based on body mass index (BMI) and existing health conditions. Eligibility is not automatic upon application; patients must demonstrate both the physiological need and willingness to engage with accompanying lifestyle programmes.

Available medications and their active ingredients

Mounjaro (tirzepatide) cohort system

The NHS has structured access to Mounjaro through three cohorts, each with distinct eligibility windows. From June 2025, Cohort 1 covers patients with a BMI of 40 or above (or 37.5 for minority ethnic groups) who also have at least four of five specified comorbidities: type 2 diabetes, hypertension, dyslipidaemia, cardiovascular disease, and obstructive sleep apnoea.

Cohort 2, beginning June 2026, extends access to those with BMI between 35 and 39.9 who meet the same comorbidity threshold. Cohort 3, launching April 2027, will include patients with BMI of 40 or above but only three comorbidities, gradually broadening the eligibility net.

Diabetes-specific eligibility

For patients with type 2 diabetes, additional prescription pathways exist. Those with a BMI of 35 or above who also experience psychological or medical obesity complications may qualify. Individuals with a BMI below 35 may also be eligible if insulin therapy carries occupational risks or exacerbates existing complications.

Tirzepatide has been approved for type 2 diabetes management alongside weight reduction when triple oral therapy has proven insufficient, according to guidance from Integrated Care Boards across England.

• BMI threshold of 40+ (or 37.5 for minority ethnic groups)
• At least 4 of 5 specified weight-related conditions
• Full participation in lifestyle support programmes
• Prescription through specialist weight management services
• Gradual expansion through phased cohorts through 2027

Patients uncertain whether they meet the criteria should consult their GP or a Tier 3 specialist weight management service for formal assessment.

Can I get Mounjaro on the NHS for weight loss?

Accessing Mounjaro through the NHS requires navigating a structured assessment process. The medication is not available on demand; patients must first demonstrate they meet the clinical threshold for obesity treatment and then be referred through the appropriate NHS channels.

Referral and assessment process

Initial assessment typically begins with a GP referral to a specialist weight management service. From March 2025, these specialist services became the sole entry point for new Mounjaro prescriptions, though expansion to primary care is anticipated as the programme matures. Patients undergo comprehensive evaluation including BMI measurement, review of existing health conditions, and discussion of previous weight management attempts.

The evaluation also considers willingness to engage with the full support programme. NHS guidance states that patients must commit to dietary changes, increased physical activity, and regular monitoring throughout the treatment period. Those unwilling or unable to participate in the wraparound support element are unlikely to receive a prescription regardless of their BMI and comorbidities.

Regional variations in access

Implementation varies across Integrated Care Boards (ICBs). Some regions, such as Northeast and North Cumbria, require completion of a full care plan before treatment initiation. Others, including Cheshire and Merseyside, follow the national interim guidance closely while maintaining local flexibility in service delivery.

The rollout follows a national framework, but ICBs determine how services are structured within their areas. Patients should check with their local NHS trust for specific requirements in their region.

Those currently obtaining Mounjaro privately may switch to NHS prescriptions only if they subsequently meet NHS eligibility criteria. Boots and similar private providers operate under different assessment frameworks and do not guarantee NHS prescription eligibility.

How much do NHS weight loss injections cost?

For patients meeting the eligibility criteria, NHS weight loss injections are provided free at the point of use. The medication, administration, and associated monitoring are funded through standard NHS commissioning arrangements rather than as standalone prescriptions.

NHS funding structure

The cost of Mounjaro, Wegovy, and Saxenda is borne by the NHS through commissioning variations rather than individual prescription charges. Patients do not pay the standard prescription levy, and those exempt from prescription charges entirely receive these medications without any payment obligation.

Funding flows through ICBs as part of specialised weight management service contracts. Individual hospitals and clinics do not bill patients separately for the medication itself, though associated services such as dietary counselling may be provided through different care pathways.

Private treatment costs

Private alternatives exist for patients who do not meet NHS criteria or wish to access treatment more quickly. Boots, for example, offers an obesity treatment service through its pharmacies. However, these private options require out-of-pocket payment and operate independently of NHS eligibility assessments.

Those considering private treatment should note that switching from private to NHS care requires meeting the full NHS eligibility criteria at the time of application. Private prescriptions do not automatically translate to NHS continuation.

What are the side effects of NHS weight loss injections?

Weight loss injections work by mimicking gut hormones to reduce appetite and regulate blood sugar levels. As with all medications, they carry potential side effects that patients should understand before starting treatment.

Common adverse effects

Clinical guidance identifies several commonly reported side effects across the GLP-1 receptor agonist class, which includes tirzepatide (Mounjaro), semaglutide (Wegovy), and liraglutide (Saxenda). Gastrointestinal symptoms predominate, with nausea affecting a significant proportion of patients during initial treatment phases.

• Nausea and vomiting
• Diarrhoea or constipation
• Abdominal discomfort or pain
• Reduced appetite
• Fatigue in early treatment stages

Most gastrointestinal side effects tend to diminish as the body adjusts to the medication, typically within the first few weeks. Dose escalation is often managed gradually to help minimise these symptoms.

Rare but serious risks

Less common but more serious potential complications include inflammation of the pancreas (pancreatitis) and gallbladder problems. Patients experiencing severe abdominal pain, particularly if accompanied by vomiting, should seek medical attention promptly.

All side effects should be reported to the prescribing clinician. Regular monitoring throughout treatment allows for dose adjustment or medication changes if adverse effects prove problematic. The decision to continue, modify, or discontinue treatment is made jointly between patient and clinician based on individual response and tolerance.

It is essential to note that side effect profiles may vary between the three available medications. Detailed information should be discussed with the prescribing specialist weight management service.

Where can I get weight loss injections in the UK, including Scotland and Boots?

Availability of NHS weight loss injections varies across the United Kingdom. The national rollout applies across England, Scotland, and Wales, though implementation details differ by region. Private options provide alternative access for those ineligible for NHS treatment.

England NHS services

In England, specialist weight management services operate as the primary gateway to NHS weight loss injections. GP referrals connect patients to these services, which conduct full clinical assessment and, if eligible, initiate and monitor treatment. Services are commissioned through ICBs, resulting in some variation across regions.

The Herts and West Essex area announced expanded access from June 2025, prioritising patients with the highest clinical need. Similar expansions are occurring across other ICBs as capacity allows within the phased rollout framework.

Primary care prescription capability is expected to expand as the programme matures, potentially simplifying access in the future. Patients should monitor announcements from their local NHS trust regarding service availability.

Scotland and UK-wide access

Scotland follows the national UK rollout framework, though specific Scottish Health Board implementation details may differ from English ICB arrangements. Evidence of Scotland-specific criteria is limited in current NHS guidance; the national framework appears to apply across all UK nations.

Patients in Scotland should consult their GP or local health board for region-specific information. The Scottish Medicines Consortium provides separate guidance for medicines approval in Scotland, though weight loss injections appear to operate under UK-wide arrangements.

Private providers and Boots

Boots offers private obesity treatment services through its pharmacy network. These operate independently of NHS eligibility criteria, allowing patients who do not meet NHS thresholds to access weight loss injections privately. However, costs are borne entirely by the patient.

Private providers conduct their own assessments using different criteria than the NHS. This means a patient approved for private treatment may not qualify for NHS-prescribed medication. Those considering private routes should understand that NHS switching requires meeting full NHS eligibility requirements.

The existence of private options does not affect NHS access pathways. Patients continue to need GP referral and specialist assessment regardless of private alternatives available in the market.

How has the NHS rollout of weight loss injections developed over time?

1. Wegovy and Saxenda available: Ongoing access through specialist services with phased primary care expansion.
2. March 2025: Specialist weight management services become the sole gateway for new Mounjaro prescriptions in England.
3. June 2025: Cohort 1 eligibility activates, covering BMI 40+ patients with four or more comorbidities.
4. 2025: Regional service expansions, including Herts and West Essex, begin prioritising highest-need patients.
5. June 2026: Cohort 2 activates, extending access to BMI 35–39.9 with four+ comorbidities.
6. April 2027: Cohort 3 activates, covering BMI 40+ with three+ comorbidities.
7. Ongoing: Primary care prescription expansion planned as programme capacity increases.

The phased approach reflects the scale of demand and the need to manage resources effectively while ensuring the most severely affected patients receive access first.

What is known and what remains unclear about NHS weight loss injections?

The programme remains relatively new, and long-term outcome data continues to accumulate. Patients should maintain realistic expectations about both benefits and limitations of treatment.

Why are weight loss injections being prioritised by the NHS?

Obesity represents one of the most significant public health challenges facing the NHS. The condition contributes to type 2 diabetes, cardiovascular disease, certain cancers, and reduced life expectancy. Addressing obesity through effective medical interventions aligns with the NHS Long Term Plan’s focus on prevention and management of chronic conditions.

Weight loss injections offer a different approach from previous pharmaceutical options. By mimicking gut hormones, they address underlying appetite regulation rather than simply suppressing hunger. Clinical trials demonstrated meaningful weight reduction in patients meeting specific criteria, leading to NICE approval for NHS use.

The investment in specialist weight management services reflects recognition that medication alone is insufficient. Successful treatment requires comprehensive lifestyle support, and the NHS has structured services accordingly. This integrated approach aims to deliver sustainable weight management rather than temporary results.

Prioritisation through phased cohorts ensures resources concentrate on patients with greatest clinical need. The approach also allows monitoring of outcomes and service capacity before broader expansion.

NHS access to weight loss injections like Mounjaro, Wegovy, and Saxenda is restricted to eligible patients with obesity, prescribed alongside diet, exercise, and lifestyle support programmes, with a phased rollout prioritising highest clinical need.

NHS England guidance on weight management injections

What steps should patients take to explore NHS weight loss injection options?

Patients interested in NHS weight loss injections should begin by consulting their GP. The GP can assess initial eligibility, provide information about local specialist services, and initiate referral if appropriate. Self-referral is not currently available; all patients must pass through primary care to access specialist weight management services.

During the initial consultation, patients should be prepared to discuss their weight history, previous attempts at weight management, existing health conditions, and commitment to lifestyle changes. Documentation of height, weight, and any related health conditions facilitates assessment.

Understanding that treatment involves more than medication is crucial. The wraparound support element requires active participation in dietary guidance, exercise programmes, and regular monitoring appointments. Patients unwilling to engage with these components are unlikely to receive prescriptions regardless of clinical eligibility.

Those who do not meet NHS criteria but wish to pursue treatment may explore private options such as Boots obesity services. However, private treatment carries full cost responsibility and does not guarantee future NHS access without meeting eligibility requirements.

Regular monitoring of local NHS announcements helps patients stay informed about expanding access and changing eligibility criteria as the programme develops.

Frequently asked questions